This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. Clinical trials underway for multiple solid tumors. #Oncology #Biotech
2026-05-15T04:37:44.874Z